Published in Hum Immunol on November 01, 2001
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A (2005) 2.11
Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res (2008) 2.07
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity. J Immunol (2009) 1.57
Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res (2002) 1.52
Application of pharmacogenomics to vaccines. Pharmacogenomics (2009) 1.30
Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One (2007) 1.30
Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinformatics (2009) 1.23
Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires. Immunogenetics (2005) 1.18
Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol (2008) 1.11
Characterization of the peptide-binding specificity of Mamu-A*11 results in the identification of SIV-derived epitopes and interspecies cross-reactivity. Immunogenetics (2005) 1.11
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine (2010) 1.04
Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules. Immunogenetics (2006) 1.03
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol (2014) 1.03
HLA class I allele promiscuity revisited. Immunogenetics (2011) 0.99
A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog (2009) 0.97
Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine (2009) 0.96
HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine (2009) 0.94
Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. Vaccine (2009) 0.92
HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. Infect Immun (2005) 0.92
A comparative molecular similarity index analysis (CoMSIA) study identifies an HLA-A2 binding supermotif. J Comput Aided Mol Des (2003) 0.90
Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med (2005) 0.89
An asymmetric model of heterozygote advantage at major histocompatibility complex genes: degenerate pathogen recognition and intersection advantage. Genetics (2008) 0.89
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Elife (2016) 0.88
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One (2013) 0.87
Human CD8⁺ and CD4⁺ T cell memory to lymphocytic choriomeningitis virus infection. J Virol (2011) 0.85
Peptide-binding motifs associated with MHC molecules common in Chinese rhesus macaques are analogous to those of human HLA supertypes and include HLA-B27-like alleles. Immunogenetics (2013) 0.85
Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1*02601 and Mamu-B*08301 reveals HLA-A2 and HLA-A3 supertypic specificities. Immunogenetics (2011) 0.84
HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLoS One (2012) 0.84
Statistical deconvolution of enthalpic energetic contributions to MHC-peptide binding affinity. BMC Struct Biol (2006) 0.83
The frequency of Chlamydia trachomatis major outer membrane protein-specific CD8+ T lymphocytes in active trachoma is associated with current ocular infection. Infect Immun (2006) 0.81
The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS One (2013) 0.80
Incidental CD8 T cell reactivity against caspase-cleaved apoptotic self-antigens from ubiquitously expressed proteins in islets from prediabetic human leucocyte antigen-A2 transgenic non-obese diabetic mice. Clin Exp Immunol (2011) 0.80
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One (2014) 0.79
HLAsupE: an integrated database of HLA supertype-specific epitopes to aid in the development of vaccines with broad coverage of the human population. BMC Immunol (2016) 0.77
Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development. Hum Vaccin Immunother (2014) 0.77
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer. Int J Oncol (2014) 0.76
Identification and functional perspective of a novel HLA-A allele: A*0279. Immunogenetics (2006) 0.76
A shared MHC supertype motif emerges by convergent evolution in macaques and mice, but is totally absent in human MHC molecules. Immunogenetics (2012) 0.76
Promiscuous Recognition of a Trypanosoma cruzi CD8+ T Cell Epitope among HLA-A2, HLA-A24 and HLA-A1 Supertypes in Chagasic Patients. PLoS One (2016) 0.75
Short peptide epitope design from hantaviruses causing HFRS. Bioinformation (2017) 0.75
The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget (2017) 0.75
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science (1992) 5.25
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (1996) 3.47
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Epidermal Langerhans cells--a target for HTLV-III/LAV infection. J Invest Dermatol (1987) 3.41
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation (2001) 3.15
Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol (2002) 3.13
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Purification and reconstitution of functional lactose carrier from Escherichia coli. J Biol Chem (1981) 2.93
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Human B-cell alloantigens DC1, MT1, and LB12 are identical to each other but distinct from the HLA-DR antigen. Proc Natl Acad Sci U S A (1981) 2.86
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 2.77
Structure of HLA antigens: amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. Proc Natl Acad Sci U S A (1976) 2.71
Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 2.68
Immunological self, nonself discrimination. Science (1987) 2.59
Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation (1999) 2.59
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Purification, reconstitution, and characterization of the lac permease of Escherichia coli. Methods Enzymol (1986) 2.32
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol (1981) 2.30
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A (2000) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med (1998) 2.13
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet (2001) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med (1978) 2.11
Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation (1996) 2.10
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science (1994) 1.99
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest (1993) 1.94
Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol (2000) 1.84
Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity (1995) 1.83
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation (2001) 1.81
Characterization of a monoclonal antibody that defines an immunoregulatory T cell subset for immunoglobulin synthesis in humans. Proc Natl Acad Sci U S A (1980) 1.81
Solubilization and reconstitution of the lactose transport system from Escherichia coli. J Biol Chem (1980) 1.81
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (1989) 1.80
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol (1993) 1.78
Detection of antigens specific for B-lymphoid cultured cell lines with human alloantisera. J Exp Med (1975) 1.76
A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology (1999) 1.75
Isolation and immunologic characterization of a human. B-lymphocyte-specific, cell surface antigen. J Exp Med (1976) 1.74
Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci U S A (1989) 1.73
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest (2001) 1.72
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res (1998) 1.72